Tranexamic acid for IntraCerebral Haemorrhage TICH-2
Research type
Research Study
Full title
Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage TICH-2
IRAS ID
111168
Contact name
Nikola Sprigg
Eudract number
2012-004108-37
ISRCTN Number
N/A
Research summary
When someone has a stroke caused by bleeding into the brain (haemorrhagic stroke) permanent brain damage can occur and result in long term disability. There is also a chance that the bleeding can increase, which may cause worse disability or be life threatening. At present there is no effective treatment available to reduce the bleeding in the brain and improving the recovery. New treatments are being developed to treat stroke, but it can be very hard to test whether they work in the first few hours because often patients take longer than this to get to hospital and have investigations such as brain scanning. Also some treatments are not suitable for all patients. In this trial, the aim is to test whether it is possible to give tranexamic acid to patients in the first few hours after a haemorrhagic stroke and find out if it reduces the chances of dying and being left with disability. Tranexamic acid encourages blood to clot to stop bleeding. Continued or increased bleeding into the brain (so called haematoma expansion) is not uncommon in the first hours and days following a haemorrhagic stroke and increases the risk of the patient not recovering fully and being left with some disability, or dying. Stopping the bleeding in the first hours after stroke with medications might help patients to recover better and reduce the number of patients who die. The data will help doctors decide whether blood thickening treatments like tranexamic acid can be used in patients with acute haemorrhagic strokes to try and reduce death and disability and improve recovery.
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
12/EM/0369
Date of REC Opinion
23 Nov 2012
REC opinion
Further Information Favourable Opinion